within Pharmacolibrary.Drugs.ATC.V;

model V03AE02
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 0.0,
    adminDuration  = 600,
    adminMass      = 800 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.001,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.016666666666666666,
    Tlag           = 0
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>V03AE02</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>0</td></tr></table><p>Sevelamer is a non-absorbed, non-metallic, phosphate binding polymer used to control hyperphosphatemia in patients with chronic kidney disease (CKD) on dialysis. It is approved and commonly used in adult and pediatric patients requiring phosphate control.</p><h4>Pharmacokinetics</h4><p>Sevelamer is not systemically absorbed; therefore, traditional pharmacokinetic parameters cannot be determined in healthy or CKD populations. Its effects are localized to the gut, where it binds phosphate.</p><h4>References</h4><ol><li><p>Pierce, D, et al., &amp; Smyth, M (2011). The effect of sevelamer carbonate and lanthanum carbonate on the pharmacokinetics of oral calcitriol. <i>Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association</i> 26(5) 1615–1621. DOI:<a href=&quot;https://doi.org/10.1093/ndt/gfq598&quot;>10.1093/ndt/gfq598</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/20921291/&quot;>https://pubmed.ncbi.nlm.nih.gov/20921291</a></p></li><li><p>Freemont, AJ (2006). Lanthanum carbonate. <i>Drugs of today (Barcelona, Spain : 1998)</i> 42(12) 759–770. DOI:<a href=&quot;https://doi.org/10.1358/dot.2006.42.12.1025698&quot;>10.1358/dot.2006.42.12.1025698</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/17285149/&quot;>https://pubmed.ncbi.nlm.nih.gov/17285149</a></p></li><li><p>Brønden, A, et al., &amp; Knop, FK (2015). Sevelamer in a diabetologist&#x27;s perspective: a phosphate-binding resin with glucose-lowering potential. <i>Diabetes, obesity &amp; metabolism</i> 17(2) 116–120. DOI:<a href=&quot;https://doi.org/10.1111/dom.12355&quot;>10.1111/dom.12355</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/25041567/&quot;>https://pubmed.ncbi.nlm.nih.gov/25041567</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end V03AE02;
